- Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
- Masonic Cancer Center, University of Minnesota to Present Data in Poster Presentation Human Data Readout for Phase 1 Study to Evaluate HCW9218 in Solid Tumors at SITC 38th Annual Meeting
- HCW Biologics Participating at H.C. Wainwright 25th Annual Global Investment Conference in New York on September 11 – 13, 2023
Key statistics
On Wednesday, HCW Biologics Inc (HCWB:NMQ) closed at 1.38, 51.30% above the 52 week low of 0.91 set on Nov 15, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.30 |
---|---|
High | 1.38 |
Low | 1.26 |
Bid | 1.15 |
Offer | 1.63 |
Previous close | 1.40 |
Average volume | 3.98k |
---|---|
Shares outstanding | 37.82m |
Free float | 18.18m |
P/E (TTM) | -- |
Market cap | 52.95m USD |
EPS (TTM) | -0.6953 USD |
Data delayed at least 15 minutes, as of May 01 2024 20:44 BST.
More ▼